China Pharma Holdings, Inc. (CPHI) - 10-K Summary
Business Context and Reporting Period
Company: China Pharma Holdings, Inc. (CPHI)
Reporting Period: Fiscal Year Ended December 31, 2025
Structure: Nevada holding company; operations conducted via wholly-owned subsidiary Hainan Helpson Medical and Biotechnology Co., Ltd. ("Helpson") in the PRC.
Operations: Development, manufacture, and marketing of pharmaceutical products (generic drugs, first-to-market generics, and Traditional Chinese Medicines) and healthcare products (masks, sanitizers). Products are sold primarily to hospitals and OTC pharmacies in China.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $4.14 million | $4.53 million |
| Cost of Revenue | $4.28 million | $6.51 million |
| Gross Loss | $(0.13) million | $(1.99) million |
| Gross Margin | -3.2% | -43.8% |
| Operating Loss | $(3.24) million | $(4.59) million |
| Net Loss | $(3.19) million | $(4.74) million |
| Loss Per Share (Basic/Diluted) | $(0.74) | $(2.71) |
| Cash and Cash Equivalents | $0.35 million | $0.63 million |
| Working Capital Deficit | $(5.05) million | $(1.75) million |
| Total Debt (Lines of Credit) | $1.98 million (Current) | $2.41 million (Total) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 8.5% to $4.14 million. The "Anti-Viral/Infection & Respiratory" category dropped 10% due to products failing consistency evaluations required for centralized procurement. The "Other" category fell 61% due to market volatility in Vitamin B6 sales.
- Improved Gross Margin: Gross loss margin improved significantly from -43.8% to -3.2%. This was driven by a $1.1 million reduction in depreciation (assets fully depreciated) and lower inventory obsolescence provisions.
- Intangible Asset Expansion: Intangible assets increased from $6.7 million to $24.1 million due to the acquisition of multiple invention patents (e.g., Ipragliflozin, Captopril microcapsule) paid for via stock issuances.
- Accounts Receivable Cleanup: Gross accounts receivable dropped from $13.8 million to $0.25 million following a massive write-off of $13.7 million in uncollectible long-outstanding receivables.
- Stock Splits: A 1-for-10 reverse stock split was implemented in April 2025 (following a 1-for-5 split in 2024), reducing share count and adjusting per-share metrics retroactively.
Guidance, Outlook, Risks, and Contingencies
- Going Concern Warning: Auditors have raised substantial doubt about the Company's ability to continue as a going concern due to recurring losses, a working capital deficit, and accumulated deficit of $47.2 million. Management plans to rely on related-party advances (currently $1.44 million from the CEO), cost-cutting measures, and potential new product launches (nutrition products) to fund operations for the next 12 months.
- Regulatory Risks: Operations are heavily dependent on PRC regulations, including the National Medical Products Administration (NMPA) consistency evaluations and centralized volume-based procurement (CP). Failure to pass these evaluations excludes products from government tenders, directly impacting revenue.
- Internal Controls: Management identified a material weakness in internal control over financial reporting due to a lack of personnel knowledgeable in U.S. GAAP.
- HFCAA Compliance: The Company is subject to the Holding Foreign Companies Accountable Act (HFCAA). While the current auditor is subject to PCAOB inspection, future impediments could lead to delisting.
- Outlook: No specific financial guidance was provided. The Company is exploring Contract Manufacturing Organization (CMO) services and digital healthcare solutions to diversify revenue.
Investor Verification Checklist
- Liquidity Sustainability: Verify the continued availability of capital advances from the CEO (Zhilin Li) and related parties, as the Company has no other significant cash reserves.
- Consistency Evaluation Status: Confirm the status of key products (e.g., Roxithromycin, Cefaclor) regarding NMPA consistency evaluations, as failure to pass blocks access to major government procurement channels.
- Intangible Asset Valuation: Review the valuation and amortization schedules of the $17.9 million in intangible assets acquired via stock issuance in 2025 to ensure they represent fair value and future economic benefit.
- Accounts Receivable Quality: Assess the remaining $0.24 million in net receivables to ensure the massive write-off in 2025 resolved all significant collection risks.
- Internal Control Remediation: Monitor progress on hiring U.S. GAAP-compliant accounting personnel to address the material weakness in financial reporting.